Kimberly-Clark Announces First Quarter 2014 Results
Executive Summary
- First quarter 2014 net sales of
$5.3 billion decreased 1 percent compared to the year-ago period. Organic sales rose 4 percent, including a 12 percent increase inK-C International . Organic sales exclude the impact of changes in foreign currency exchange rates and lower sales as a result of European strategic changes and pulp and tissue restructuring actions. - Diluted net income per share for the first quarter was
$1.41 in 2014 and$1.36 in 2013. - First quarter adjusted earnings per share were
$1.48 in 2014, even with the year-ago period. Performance benefited from organic sales growth, cost savings and lower selling, general and administrative expenses. On the other hand, comparisons were negatively impacted by unfavorable foreign currency exchange rates, input cost inflation and a high level of other income in the year-ago period. Adjusted earnings per share in both years exclude certain items described later in this press release. - The company continues to expect that adjusted earnings per share in 2014 will be between
$6.00 and$6.20 .
Chairman and Chief Executive Officer
First Quarter 2014 Operating Results
Sales of
Operating profit was
The year-over-year adjusted operating profit comparison benefited from organic sales growth, $70 million in cost savings from the company's FORCE (Focused On Reducing Costs Everywhere) program and
The first quarter effective tax rate was 31.0 percent in 2014 compared to 30.9 percent in 2013. The first quarter adjusted effective tax rate, which does not include the effects of the previously mentioned items excluded from adjusted earnings per share calculations, was 29.8 percent in 2014 and 30.8 percent in 2013. The company continues to expect a full-year 2014 adjusted effective tax rate between 31 and 32.5 percent.
Cash provided by operations in the first quarter of 2014 was
Capital spending for the first quarter was $258 million in 2014 and $274 million in 2013. First quarter 2014 share repurchases were 4.3 million shares at a cost of
First Quarter 2014 Business Segment Results
Personal Care Segment
First quarter sales of
Sales in
Sales in
Sales in
Consumer Tissue Segment
First quarter sales of
Sales in
Sales in
Sales in
K-C Professional (KCP) Segment
First quarter sales of
Sales in
Sales in
Sales in
Health Care Segment
First quarter sales of
Medical device volumes were up double-digits, with strong growth in pain management products and a solid increase in digestive health offerings. Surgical and infection prevention volumes were down low-single digits, as declines in exam gloves were mostly offset by increases in other surgical product categories.
Potential Health Care Business Spin-Off - Update
In
Western and Central European Businesses Strategic Changes - Update
In
Non-GAAP Financial Measures
This press release and the accompanying tables include the following financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S., or GAAP, and are therefore referred to as non-GAAP financial measures:
- Adjusted earnings and earnings per share
- Adjusted gross and operating profit
- Adjusted other (income) and expense, net
- Adjusted effective tax rate
These non-GAAP financial measures exclude the following items for the relevant time periods as indicated in the accompanying non-GAAP reconciliations to the comparable GAAP financial measures:
- Charge related to regulatory dispute in the
Middle East . In the first quarter of 2014, the company recorded a non-deductible charge as a result of an adverse court ruling regarding the treatment of capital contributions in prior years to a majority-owned affiliate in theMiddle East .Kimberly-Clark is appealing the ruling. - Transaction and related costs for the company's potential spin-off of its health care business. (See previous discussion in this press release.)
- Western and
Central Europe strategic changes and related restructuring charges. (See previous discussion in this press release.) - Balance sheet remeasurement charge due to devaluation of Venezuelan bolivar. In the first quarter of 2013, the company recorded a charge for the remeasurement of the local currency-denominated balance sheet due to the
February 2013 devaluation of the Venezuelan bolivar.
In addition, this press release includes information regarding organic sales, which exclude the impact of changes in foreign currency rates and lower sales in conjunction with European strategic changes and pulp and tissue restructuring actions.
The company provides these non-GAAP financial measures as supplemental information to our GAAP financial measures. Management and the company's Board of Directors use adjusted earnings, adjusted earnings per share and adjusted gross and operating profit to (a) evaluate the company's historical and prospective financial performance and its performance relative to its competitors, (b) allocate resources and (c) measure the operational performance of the company's business units and their managers. Management also believes that the use of adjusted effective tax rate provides improved insight into the tax effects of our ongoing business operations.
Additionally, the
Conference Call
A conference call to discuss this news release and other matters of interest to investors and analysts will be held at
About
Copies of
Certain matters contained in this news release concerning the outlook, anticipated financial and operating results, anticipated currency rates and exchange risks, raw material, energy and other input costs, growth initiatives, the effective tax rate, the anticipated costs, scope, timing and financial and other effects of the potential spin-off of the health care business and the Western and
|
| ||||||||||
|
CONSOLIDATED INCOME STATEMENT | ||||||||||
|
(Millions, except per share amounts) | ||||||||||
|
Three Months Ended |
||||||||||
|
2014 |
2013 |
Change | ||||||||
|
Net Sales |
$ |
5,278 |
$ |
5,318 |
-0.8% | |||||
|
Cost of products sold |
3,453 |
3,496 |
-1.2% | |||||||
|
Gross Profit |
1,825 |
1,822 |
+0.2% | |||||||
|
Marketing, research and general expenses |
971 |
1,027 |
-5.5% | |||||||
|
Other (income) and expense, net |
57 |
12 |
N.M. | |||||||
|
Operating Profit |
797 |
783 |
+1.8% | |||||||
|
Interest income |
3 |
5 |
-40.0% | |||||||
|
Interest expense |
(71) |
(67) |
+6.0% | |||||||
|
Income Before Income Taxes and Equity Interests |
729 |
721 |
+1.1% | |||||||
|
Provision for income taxes |
(226) |
(223) |
+1.3% | |||||||
|
Income Before Equity Interests |
503 |
498 |
+1.0% | |||||||
|
Share of net income of equity companies |
43 |
53 |
-18.9% | |||||||
|
Net Income |
546 |
551 |
-0.9% | |||||||
|
Net income attributable to noncontrolling interests |
(8) |
(20) |
-60.0% | |||||||
|
Net Income Attributable to |
$ |
538 |
$ |
531 |
+1.3% | |||||
|
Per Share Basis |
||||||||||
|
Net Income Attributable to |
||||||||||
|
Basic |
$ |
1.42 |
$ |
1.37 |
+3.6% | |||||
|
Diluted |
$ |
1.41 |
$ |
1.36 |
+3.7% | |||||
|
Cash Dividends Declared |
$ |
0.84 |
$ |
0.81 |
+3.7% | |||||
|
Common Shares Outstanding |
|
|||||||||
|
2014 |
2013 |
|||||||||
|
Outstanding shares as of |
377.2 |
384.7 |
||||||||
|
Average diluted shares for three months ended |
382.1 |
390.5 |
||||||||
|
N.M. - Not Meaningful |
|
Unaudited |
|
| ||||||||||||||||||||
|
NON-GAAP RECONCILIATIONS | ||||||||||||||||||||
|
(Millions, except per share amounts) | ||||||||||||||||||||
|
Three Months Ended | ||||||||||||||||||||
|
As Reported |
Charges for European Strategic Changes |
Charges Related to Health Care Spin-off |
Charge Related to Regulatory Dispute in |
As Adjusted Non-GAAP | ||||||||||||||||
|
Cost of products sold |
$ |
3,453 |
$ |
6 |
$ |
— |
$ |
— |
$ |
3,447 |
||||||||||
|
Gross profit |
1,825 |
(6) |
— |
— |
1,831 |
|||||||||||||||
|
Marketing, research and general expenses |
971 |
4 |
7 |
— |
960 |
|||||||||||||||
|
Other (income) and expense, net |
57 |
— |
— |
39 |
18 |
|||||||||||||||
|
Operating profit |
797 |
(10) |
(7) |
(39) |
853 |
|||||||||||||||
|
Income before income taxes and equity interests |
729 |
(10) |
(7) |
(39) |
785 |
|||||||||||||||
|
Provision for income taxes |
(226) |
5 |
3 |
— |
(234) |
|||||||||||||||
|
Effective tax rate |
31.0% |
— |
— |
— |
29.8% |
|||||||||||||||
|
Income before equity interests |
503 |
(5) |
(4) |
(39) |
551 |
|||||||||||||||
|
Net income |
546 |
(5) |
(4) |
(39) |
594 |
|||||||||||||||
|
Net income attributable to noncontrolling interests |
(8) |
— |
— |
20 |
(28) |
|||||||||||||||
|
Net income attributable to |
538 |
(5) |
(4) |
(19) |
566 |
|||||||||||||||
|
Diluted earnings per share |
1.41 |
(0.01) |
(0.01) |
(0.05) |
1.48 |
|||||||||||||||
|
Three Months Ended | ||||||||||||||||||||
|
As Reported |
Charges for European Strategic Changes |
Charge for Venezuelan Bolivar Devaluation |
As Adjusted Non-GAAP | |||||||||||||||||
|
Cost of products sold |
$ |
3,496 |
$ |
20 |
$ |
— |
$ |
3,476 |
||||||||||||
|
Gross profit |
1,822 |
(20) |
— |
1,842 |
||||||||||||||||
|
Marketing, research and general expenses |
1,027 |
11 |
— |
1,016 |
||||||||||||||||
|
Other (income) and expense, net |
12 |
— |
36 |
(24) |
||||||||||||||||
|
Operating profit |
783 |
(31) |
(36) |
850 |
||||||||||||||||
|
Income before income taxes and equity interests |
721 |
(31) |
(36) |
788 |
||||||||||||||||
|
Provision for income taxes |
(223) |
10 |
10 |
(243) |
||||||||||||||||
|
Effective tax rate |
30.9% |
— |
— |
30.8% |
||||||||||||||||
|
Income before equity interests |
498 |
(21) |
(26) |
545 |
||||||||||||||||
|
Net income |
551 |
(21) |
(26) |
598 |
||||||||||||||||
|
Net income attributable to |
531 |
(21) |
(26) |
578 |
||||||||||||||||
|
Diluted earnings per share |
1.36 |
(0.05) |
(0.07) |
1.48 |
||||||||||||||||
|
Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for the comparable GAAP measures, and they should be read only in conjunction with the company's consolidated financial statements prepared in accordance with GAAP. There are limitations to these non-GAAP financial measures because they are not prepared in accordance with GAAP and may not be comparable to similarly titled measures of other companies due to potential differences in methods of calculation and items being excluded. The company compensates for these limitations by using these non-GAAP financial measures as a supplement to the GAAP measures and by providing reconciliations of the non-GAAP and comparable GAAP financial measures. |
|
Unaudited |
|
| |||||||
|
CONSOLIDATED BALANCE SHEET | |||||||
|
(Millions) | |||||||
|
2014 |
2013 | ||||||
|
ASSETS |
|||||||
|
Current Assets |
|||||||
|
Cash and cash equivalents |
$ |
1,165 |
$ |
1,054 |
|||
|
Accounts receivable, net |
2,618 |
2,545 |
|||||
|
Inventories |
2,285 |
2,233 |
|||||
|
Other current assets |
580 |
718 |
|||||
|
Total Current Assets |
6,648 |
6,550 |
|||||
|
Property, Plant and Equipment, Net |
7,841 |
7,948 |
|||||
|
Investments in Equity Companies |
419 |
382 |
|||||
|
Goodwill |
3,210 |
3,181 |
|||||
|
Other Intangible Assets |
232 |
243 |
|||||
|
Other Assets |
652 |
615 |
|||||
|
TOTAL ASSETS |
$ |
19,002 |
$ |
18,919 |
|||
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|||||||
|
Current Liabilities |
|||||||
|
Debt payable within one year |
$ |
927 |
$ |
375 |
|||
|
Redeemable preferred securities of subsidiary |
506 |
506 |
|||||
|
Trade accounts payable |
2,553 |
2,598 |
|||||
|
Accrued expenses |
1,955 |
2,060 |
|||||
|
Dividends payable |
318 |
309 |
|||||
|
Total Current Liabilities |
6,259 |
5,848 |
|||||
|
Long-Term Debt |
5,385 |
5,386 |
|||||
|
Noncurrent Employee Benefits |
1,133 |
1,312 |
|||||
|
Deferred Income Taxes |
894 |
817 |
|||||
|
Other Liabilities |
334 |
344 |
|||||
|
|
72 |
72 |
|||||
|
Stockholders' Equity |
|||||||
|
|
4,668 |
4,856 |
|||||
|
Noncontrolling Interests |
257 |
284 |
|||||
|
Total Stockholders' Equity |
4,925 |
5,140 |
|||||
|
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY |
$ |
19,002 |
$ |
18,919 |
|||
|
2014 Data is Unaudited |
|
| |||||||
|
CONSOLIDATED CASH FLOW STATEMENT | |||||||
|
(Millions) | |||||||
|
Three Months Ended | |||||||
|
2014 |
2013 | ||||||
|
Operating Activities |
|||||||
|
Net income |
$ |
546 |
$ |
551 |
|||
|
Depreciation and amortization |
218 |
221 |
|||||
|
Stock-based compensation |
9 |
30 |
|||||
|
Deferred income taxes |
51 |
14 |
|||||
|
Net (gains) losses on asset dispositions |
7 |
(13) |
|||||
|
Equity companies' earnings in excess of dividends paid |
(43) |
(53) |
|||||
|
(Increase) decrease in operating working capital |
(210) |
(121) |
|||||
|
Postretirement benefits |
(156) |
(55) |
|||||
|
Other |
15 |
33 |
|||||
|
Cash Provided by Operations |
437 |
607 |
|||||
|
Investing Activities |
|||||||
|
Capital spending |
(258) |
(274) |
|||||
|
Proceeds from dispositions of property |
5 |
74 |
|||||
|
Investments in time deposits |
(38) |
— |
|||||
|
Maturities of time deposits |
157 |
20 |
|||||
|
Other |
— |
1 |
|||||
|
Cash Used for Investing |
(134) |
(179) |
|||||
|
Financing Activities |
|||||||
|
Cash dividends paid |
(309) |
(289) |
|||||
|
Change in short-term borrowings |
654 |
335 |
|||||
|
Debt proceeds |
1 |
59 |
|||||
|
Debt repayments |
(101) |
(38) |
|||||
|
Cash paid on redeemable preferred securities of subsidiaries |
(7) |
(7) |
|||||
|
Proceeds from exercise of stock options |
37 |
50 |
|||||
|
Acquisitions of common stock for the treasury |
(441) |
(486) |
|||||
|
Other |
(14) |
(10) |
|||||
|
Cash Used for Financing |
(180) |
(386) |
|||||
|
Effect of Exchange Rate Changes on Cash and Cash Equivalents |
(12) |
(39) |
|||||
|
Increase (Decrease) in Cash and Cash Equivalents |
111 |
3 |
|||||
|
Cash and Cash Equivalents - Beginning of Period |
1,054 |
1,106 |
|||||
|
Cash and Cash Equivalents - End of Period |
$ |
1,165 |
$ |
1,109 |
|||
|
Unaudited |
|
| |||||||||||
|
SELECTED BUSINESS SEGMENT DATA | |||||||||||
|
(Millions) | |||||||||||
|
Three Months Ended |
|||||||||||
|
2014 |
2013 |
Change | |||||||||
|
NET SALES |
|||||||||||
|
Personal Care |
$ |
2,382 |
$ |
2,397 |
-0.6% | ||||||
|
Consumer Tissue |
1,689 |
1,718 |
-1.7% | ||||||||
|
K-C Professional |
800 |
793 |
+0.9% | ||||||||
|
Health Care |
397 |
397 |
— | ||||||||
|
Corporate & Other |
10 |
13 |
N.M. | ||||||||
|
TOTAL NET SALES |
$ |
5,278 |
$ |
5,318 |
-0.8% | ||||||
|
OPERATING PROFIT |
|||||||||||
|
Personal Care |
$ |
457 |
$ |
441 |
+3.6% | ||||||
|
Consumer Tissue |
257 |
260 |
-1.2% | ||||||||
|
K-C Professional |
136 |
143 |
-4.9% | ||||||||
|
Health Care |
72 |
44 |
+63.6% | ||||||||
|
Corporate & Other(a) |
(68) |
(93) |
N.M. | ||||||||
|
Other (income) and expense, net |
57 |
12 |
N.M. | ||||||||
|
TOTAL OPERATING PROFIT |
$ |
797 |
$ |
783 |
+1.8% | ||||||
|
(a) |
For the three months ended |
|
N.M. - Not Meaningful | |
|
Unaudited | |
|
| ||||||||||||||||||
|
SELECTED BUSINESS SEGMENT DATA | ||||||||||||||||||
|
PERCENTAGE CHANGE IN NET SALES VERSUS PRIOR YEAR | ||||||||||||||||||
|
Three Months Ended | ||||||||||||||||||
|
Total |
Organic Volume |
Restructuring Impact(a) |
Net Price |
Mix/ Other(b) |
Currency | |||||||||||||
|
Consolidated |
(0.8) |
3 |
(2) |
1 |
— |
(3) |
||||||||||||
|
Personal Care |
(0.6) |
6 |
(3) |
1 |
— |
(5) |
||||||||||||
|
Consumer Tissue |
(1.7) |
— |
(2) |
2 |
— |
(2) |
||||||||||||
|
K-C Professional |
0.9 |
2 |
— |
2 |
— |
(3) |
||||||||||||
|
Health Care |
— |
4 |
— |
(2) |
(1) |
(1) |
||||||||||||
|
(a) |
Lower sales related to the European strategic changes and pulp and tissue restructuring actions. |
|
(b) |
Mix/Other includes rounding. |
|
Unaudited | |
|
| ||||||||||
|
OUTLOOK FOR 2014 | ||||||||||
|
ESTIMATED FULL YEAR 2014 DILUTED EARNINGS PER SHARE | ||||||||||
|
| ||||||||||
|
Adjusted earnings per share |
$ |
6.00 |
- |
$ |
6.20 |
|||||
|
Adjustments for: |
||||||||||
|
Transaction and related costs associated with potential spin-off of health care business(a) |
(0.01) |
- |
(0.01) |
|||||||
|
Charge related to regulatory dispute in |
(0.05) |
- |
(0.05) |
|||||||
|
Charges for European strategic changes |
(0.07) |
- |
(0.06) |
|||||||
|
Per share basis - diluted net income attributable to |
$ |
5.87 |
- |
$ |
6.08 |
|||||
|
ESTIMATED FULL YEAR 2014 EFFECTIVE TAX RATE |
||||||||||
|
Adjusted effective tax rate |
31.0% |
- |
32.5% |
|||||||
|
Adjustments for: |
||||||||||
|
Transaction and related costs associated with potential spin-off of health care business(a) |
— |
- |
— |
|||||||
|
Charge related to regulatory dispute in |
0.4 |
- |
0.4 |
|||||||
|
Charges for European strategic changes |
0.1 |
- |
0.2 |
|||||||
|
Effective tax rate |
31.5% |
- |
33.1% |
|||||||
|
The company's 2014 projections include a full-year estimate for the operations of the health care segment. | |
|
(a) |
Represents costs through |
[KMB-F]
Logo - http://photos.prnewswire.com/prnh/20110928/DA76879LOGO
SOURCE
News Provided by Acquire Media